Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
323 hedge funds and large institutions have $5.56B invested in Apellis Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 128 funds opening new positions, 89 increasing their positions, 72 reducing their positions, and 79 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
75% more capital invested
Capital invested by funds: $3.17B → $5.56B (+$2.39B)
62% more first-time investments, than exits
New positions opened: 128 | Existing positions closed: 79
43% more call options, than puts
Call options by funds: $52.1M | Put options by funds: $36.5M
24% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 72
16% more funds holding
Funds holding: 279 → 323 (+44)
9.9% more ownership
Funds ownership: 99.89% → 109.78% (+9.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$157M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$113M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$77.3M |
| 4 |
HI
HBK Investments
Dallas,
Texas
|
+$76.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$48.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$269M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$93.1M |
| 3 |
RI
RTW Investments
New York
|
-$85.8M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$69.3M |
| 5 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$64.8M |
APLS Hedge Fund Activity: Q1 2026 in Review
323 of the 8,169 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q1 2026, worth a combined $5.56B — up 75% from $3.17B a quarter earlier.
Buyers outnumbered sellers: 128 funds opened new APLS positions and 79 closed out — a net gain of 49 holders — while 89 added to existing stakes and 72 trimmed.
The largest buyer was BlackRock, adding an estimated $157M. The largest seller was Wellington Management Group, cutting an estimated $269M.
- 323 institutional investors held Apellis Pharmaceuticals (APLS) as of Q1 2026, up from 279 in Q4 2025.
- Funds reported $5.56B of Apellis Pharmaceuticals stock for Q1 2026, up 75% quarter-over-quarter.
- 128 funds opened new Apellis Pharmaceuticals positions in Q1 2026 and 79 closed out, a net change of +49 holders.
- The largest Apellis Pharmaceuticals buyer in Q1 2026 was BlackRock, an estimated $157M added.
- The largest Apellis Pharmaceuticals seller in Q1 2026 was Wellington Management Group, an estimated $269M sold.
Based on aggregated 13F filings for Q1 2026.